Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-400 versus LONSURF plus bevacizumab in c-Met-positive refractory metastatic colorectal cancer
NL-OMON60210Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telisotuzumab adizutecan in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of participants with adverse events, Percentage of participants with potentially clinically significant vital sign measurements and 4 more. Started Jun 2026; status: completed.
02
Drugs
telisotuzumab adizutecan
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON60210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60210.